Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Patient selection is important for targeted therapies, yet phase I/II trials are often underpowered for developing predictors of drug response. The goal of this research was to define genomic predictors for dasatinib that could be prospectively tested in early-phase clinical trials. Gene expression profiles of dasatinib-sensitive and dasatinib-resistant cell lines (n = 23) were compared to develop a dasatinib-sensitivity index (modified DS index). A Src pathway activity index (revised Src index) was defined using genes induced by the Src transfection of mammary epithelial cells and was optimized to be reproducible across cell lines and human specimens. A dasatinib target index was devised using the weighted sum of 19 kinases that bind to dasatinib with variable affinity. The performance of these prediction models was assessed in independent cell lines with known dasatinib sensitivity. The feasibility of applying these genomic tests to human samples was evaluated on 133 biopsies of primary breast cancers. The modified DS index showed 90% accuracy in independent breast cancer cell lines (n = 12) and the target index, but not the revised Src index signature, also distinguished dasatinib-sensitive and dasatinib-resistant cells (P = 0.0024). The genomic predictors showed acceptable reproducibility in replicate cell line and human gene expression data. When all three predictors were applied to the same 133 patient samples, the predictors identified different patient subsets as potentially sensitive. We defined three conceptually different potential predictors of dasatinib response that were reproducible across cell lines and human data. These candidate markers are being tested in a clinical trial to determine their utility. Mol Cancer Ther; 9(5); 1120–7. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ayers, M., Symmans, W. F., Stec, J., Damokosh, A. I., Clark, E., Hess, K., Lecocke, M., Metivier, J., Booser, D., Ibrahim, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.166 · Cited by 566
Self-citationHuang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., & Clark, E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3633 · Cited by 344 · cited 5×
“Investigators have also compared the gene expression profiles of dasatinib-sensitive to dasatinib-resistant breast cancer cell lines and generated a cell line–based genomic predictor of dasatinib response (13).”
BackgroundMethodInfluentialSelf-citation
Cited by
Montero, J. C., Seoane, S., Ocaña, A., & Pandiella, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2616 · Cited by 298
“An SRC pathway activity index has also been defined to establish patients that may respond to dasatinib (39).”
Current status of SRC inhibitors in solid tumor malignancies
Puls, L. N., Eadens, M., & Messersmith, W. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0408 · Cited by 158
Src-family tyrosine kinases as therapeutic targets in advanced cancer
Gelman, I. H. (2011) · Frontiers in Bioscience · doi:10.2741/e287 · Cited by 28
Surrogate markers for targeted therapy-based treatment activity and efficacy
Bianchini, G., & Gianni, L. (2011) · JNCI Monographs · doi:10.1093/jncimonographs/lgr024 · Cited by 2
Metadata
- Authors
- Moulder, S., Yan, K., Huang, F., Hess, K. R., Liedtke, C., Lin, F., Hatzis, C., Hortobagyi, G. N., Symmans, W. F., & Pusztai, L.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2010-05-01
- Volume
- 9
- Issue
- 5
- Pages
- 1120-1127
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2105336633
- Cited by
- 33
- References
- 2
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy. https://app.cochat.ai/papers/10.1158/1535-7163.mct-09-1117
- The paper
- Moulder, S., Yan, K., Huang, F., Hess, K. R., Liedtke, C., Lin, F., Hatzis, C., Hortobagyi, G. N., Symmans, W. F., & Pusztai, L. (2010). Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-09-1117
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.